Popular search terms:
Search Results
132 results found-
CSL Behring provides protein-based therapies for bleeding disorders, critical care, pulmonary disease, and other rare illnesses.
https://www.cslbehring.com.au/products -
CSL Behring Australia's Product Information (PI), Consumer Medicine Information (CMI), Safety Data Sheets and New Zealand Data Sheet
https://www.cslbehring.com.au/products/products-list -
The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain infectious agents and by testing for the presence of certain viral markers.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/rhd-immunoglobulinvf-nz-ds-1500.pdf -
The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain infectious agents and by testing for the presence of certain viral markers.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/prothrombinexvf-nz-ds-2100.pdf -
Not classified as hazardous according to the WHS Regulations All blood products should be treated as potentially infectious.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/safety-data-sheets/sds205-prothrombinex-vf-v4.pdf -
Hazard(s) identification Not classified as hazardous according to the WHS Regulations All blood products should be treated as potentially infectious.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/safety-data-sheets/sds240-intragam-10-nf-v3.pdf -
In general, all patients treated with coagulation FVIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/biostate-nz-ds2000.pdf -
All blood products should be treated as potentially infectious.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/safety-data-sheets/sds132-rhd-immunoglobulinvf-v5.pdf -
The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain infectious agents and by testing for the presence of certain viral markers.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/rhd-immunoglobulinvf-au-pi-1500.pdf